Collplant Biotechnologies vs Vistagen Therapeutics
Collplant Biotechnologies is the larger business, with $2.4m of revenue in fiscal 2025 against $1.3m for Vistagen Therapeutics (1.9 times as much). Collplant Biotechnologies grew faster (360.4% against 161.1%). Collplant Biotechnologies kept more of each dollar of sales as profit: a net margin of -484.6% against -5491.3%.
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Vistagen TherapeuticsVTGN, 2026 |
|---|---|---|
| Revenue | $2.4m | $1.3m |
| Revenue growth | 360.4% | 161.1% |
| Net income | −$11.5m | −$69.7m |
| Operating margin | -484.3% | — |
| Net margin | -484.6% | -5491.3% |
| Return on equity | -117.6% | -131.6% |
| Free cash flow | −$9.4m | −$66.4m |
| Cash | $5.6m | $30.8m |
| Total debt | $0 | $96,000 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 41 |
| Market value | $52.2m | $7.3m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |